USPTO serial 88296676
CADEX GENOMICS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 22, 2020
- Examiner
- JAGANNATHAN, SIDDHARTH
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with CADEX GENOMICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*
Plus Government fees of $1,275
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
James K. Stronski
James K. Stronski CROWELL & MORING LLP590 MADISON AVENUE, 20TH FLOORNEW YORK, NY 10022UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medical diagnostic assays for testing of bodily fluids, namely, assays used to evaluate the effectiveness of cancer drug therapy and to identify patients who are not responding to cancer drug therapy; Medical diagnostic test media in the form of reagents used to evaluate the effectiveness of cancer drug therapy and to identify patients who are not responding to cancer drug therapy; medical diagnostic kits comprised of medical diagnostic reagents and assays used to evaluate the effectiveness of cancer drug therapy and to identify patients who are not responding to cancer drug therapy | ACTIVE | Apr 16, 2019 |
| 042 | Medical and scientific research in the field of medical diagnostic assays and clinical testing services for the purpose of testing of bodily fluids used to evaluate the effectiveness of cancer drug therapy and to identify patients who are not responding to cancer drug therapy; Research and development in the pharmaceutical and biotechnology fields, namely, research and development in the development of testing and information services related to medical diagnostic assays and clinical tests, and medical diagnostic kits used to conduct medical diagnostic assays and clinical tests | ACTIVE | Feb 25, 2019 |
| 044 | Medical testing for diagnostic or treatment purposes, namely, for the purpose of testing of bodily fluids used to evaluate the effectiveness of cancer drug therapy and to identify patients who are not responding to cancer drug therapy | ACTIVE | Jan 13, 2020 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Cadex Genomics, Corp.
- Other trademarks owned by Cadex Genomics, Corp.
- Other trademarks owned by Cadex Genomics, Corp.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named CADEX GENOMICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 22, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Sep 22, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 18, 2020 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Aug 15, 2020 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Aug 14, 2020 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Aug 13, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Aug 4, 2020 | IUAF | USE AMENDMENT FILED | — |
| Aug 4, 2020 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Feb 4, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 10, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 10, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 20, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 1, 2019 | ALIE | ASSIGNED TO LIE | — |
| Oct 28, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 26, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 25, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 25, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 29, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 29, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 29, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 23, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 5, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 14, 2019 | NWAP | NEW APPLICATION ENTERED | — |